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a b s t r a c t
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder of
immune regulation. In patients over 60 years of age, HLH associated with hematological
malignancies (hM-HLH) is the most prevalent. b-2-Microglobulin (B2M) plays an impor-
tant role in antigen presentation and immunological regulation. Elevated B2M levels
reflect T-cell activation. Objective: The aim of this study was to determine serum B2M
concentrations in adults with hM-HLH and to interpret its significance in the context of
overall survival (OS). Patients and methods: Serum B2M concentration was determined in
31 adults aged 22–84 years at the time of hM-HLH diagnosis. Lymphoid malignancy was
diagnosed in 22 patients and myeloid malignancy in 9 patients. Results: The serum
concentration of B2M was elevated in 100% of the examined patients. Mean and median
serum B2M concentrations were 5.3 and 4.2 mg/L, respectively (range 2–17 mg/L). We
have not found any significant differences in terms of the studied serum B2M concentra-
tions between patients with T/NK-cell lymphomas, B-cell lymphomas, and myeloid
malignancies. The outcome of HLH was poor in vast majority of patients with the
median OS for the entire group of 46 days. Conclusions: Elevated serum B2M level is
a frequent finding at the time of hM-HLH diagnosis in adults. It seems to be a useful
indicator of HLH for its early detection and evaluation afterward, as well as for imme-
diate therapeutic intervention. Further prospective studies answering the question whe-
ther serum B2M can be used as a prognostic factor in hM-HLH would be of interest.
© 2017 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved.
* Corresponding author at: Hematology Center Karolinska, M54, Karolinska University Hospital Huddinge, SE-141 86 Stockholm,
Sweden. Tel.: +46 8 58582663; fax: +46 8 7748725.
E-mail address: maciej.machaczka@ki.se (M. Machaczka).
Contents lists available at ScienceDirect
Acta Haematologica Polonica
journal homepage: www.elsevier.com/locate/achaemhttp://dx.doi.org/10.1016/j.achaem.2017.07.001
0001-5814/© 2017 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
z o.o. All rights reserved.
Introduction
Hemophagocytic lymphohistiocytosis (HLH), also known as
hemophagocytic syndrome, is a rare disorder with both
familial and acquired forms [1, 2]. It is an acute disorder of
immune regulation which leads to an exaggerated inflamma-
tion. Macrophages and CD8+ cytotoxic T-cells release various
pro-inflammatory mediators such as tumor necrosis factor a
(TNF-a), interleukin (IL)-6, IL-8, IL-12, and interferon-g [3–6].
These cytokines induce immune cells and cytokine produc-
tion that culminates in cytokine storm and hyperinflamma-
tion [3, 4, 7]. In response, anti-inflammatory cytokines (IL-10,
IL-18-binding protein) are produced, but they are not suffi-
cient to mitigate the excessive immune activation [8, 9].
In general, HLH is a life-threatening syndrome and has
a poor prognosis [1, 10–14]. In adult patients, acquired forms
of HLH are the most prevalent [2, 14]. Malignancy-associated
Table I – Diagnostic criteria of HLH-2004
HLH diagnosis if (A) or (B) is met:
(A) The result of molecular diagnostics confirming the presence
of mutations typical for HLH




3. Cytopenias affecting at least two of three cell lineages:
a. hemoglobin <90 g/L
b. platelets <100  109/L
c. neutrophils <1.0  109/L
4. Hypertriglyceridemia 3.0 mmol/L and/or
hypofibrinogenemia 1.5 g/L
5. Hemophagocytosis in bone marrow, spleen, or lymph nodes
6. Low or absent NK-cell activity
7. Hyperferritinemia 500 mg/L
8. Elevated concentration of soluble interleukin 2 receptor a
(sIL-2Ra/sCD25) 2400 U/mL
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in the group of patients aged 60 years, M-HLH is the most
frequent form of HLH [10]. Although the clinical presentation
of HLH may be variable, the most common signs are unremit-
ting fever, cytopenia, hepatosplenomegaly, jaundice, edema,
neurological symptoms and hemophagocytosis in bone mar-
row (BM), liver or lymph nodes [1, 7, 14]. According to the
current HLH-2004 guidelines, the diagnosis of HLH is based
on a constellation of clinical and laboratory criteria [15].
b-2-Microglobulin (B2M) is a low-molecular-weight
(11.8 kDa) protein synthesized in all nucleated cells and
constituting the light chain subunit of the major histocom-
patibility complex (MHC) class I receptor [5]. B2M plays an
important role in antigen presentation and regulation of
tumor immunological processes. Approximately 50% of B2M
is produced by lymphocytes and is freely filtered through
glomerular basement membrane. Under physiological condi-
tions B2M is produced at a constant rate. However, B2M
serum levels rise in the presence of glomerular impairment
or lymphocyte activation, as well as in patients with
hematological malignancy or systemic inflammation [5, 16].
The aim of the present study was to determine serum
B2M concentrations in adults with hematologic malignancy-
associated HLH (hM-HLH) and to interpret its significance in
the context of HLH therapy outcome.
Patients and methods
The study population consisted of 31 adult patients diag-
nosed with a hematological malignancy and HLH. The
enrolled patients were admitted to the Hematology Center
Karolinska, Karolinska University Hospital, between January
2009 and December 2016. A hematological malignancy was
defined as a neoplasm of lymphoid or myeloid origin and
the diagnosis was established according to Swedish national
standards and protocols.
In all studied patients, the diagnosis of HLH was based
on the criteria proposed by the Histiocyte Society (Table I)
[15]. Noteworthy, these criteria were developed based on
familial, inherited forms of HLH. Due to the lack of specific
guidelines for M-HLH, they are also used to diagnose it.However, majority of reports published on M-HLH were
examined six or less HLH-2004 criteria, and as a rule with-
out sIL-2Ra/sCD25 result and NK cells activity data [11, 14,
17]. Some authors argue that hyperferritinemia 10 000 mg/L
is a more specific and sensitive HLH criterion [18]. Therefore,
we included in this analysis all patients with suspected HLH
who fulfilled at least four of six HLH-2004 criteria including
at least two of three additional HLH features: sIL-2Ra
2400 U/mL, hemophagocytosis in BM, and hyperferritine-
mia 10 000 mg/L.
Fresh blood samples were drawn and directly analyzed at
the Karolinska University Laboratory according to standard
practice. The Roche B2MG Tina-Quant serum kit was used
to measure serum concentrations of B2M immunoturbidi-
metrically; normal value of serum B2M was <2.0 mg/L. The
serum ferritin concentration was assessed using Roche
Modular Analyzers (Roche Diagnostics, USA). Serum concen-
trations of sIL-2Ra were determined by ELISA, using the
quantitative ‘sandwich’ enzyme immunoassay, on the
IMMULITE® 1000 Immunoassay System (DPC Siemens).
HLH treatment categories have included proapoptotic
chemotherapy (etoposide at 50–150 mg/m2/dose i.v.) and use
of immunosuppressive drugs, targeting hyperactivated
macrophages (corticosteroids, IVIG) and T cells (corticoster-
oids, cyclosporine A). Treatment plan was individually
adopted for each patient, based on the protocol HLH-94 [19].
The patients’ medical records were reviewed to collect
relevant clinical data. The patients provided their informed
consent. The study was performed according to the ethical
guidelines of the Declaration of Helsinki.
The results are presented as a mean  standard deviation
(SD) or median and variable range. The distribution of
continuous values was assessed with the Shapiro–Wilk test.
Depending on the variable's distribution, T test or Mann–
Whitney U test was used for comparisons between indepen-
dent groups. Chi-square Pearson, Yates or Fisher tests were
used for nominal values. Overall survival (OS) was estimated
by the Kaplan–Meier method and compared with the log-
rank test. An a-level of p < 0.05 was required for signifi-
cance. Statistical analysis was performed using Statistica
version 12.0 PL software.
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Twenty-two men (71%) and 9 women (29%), aged 28–84
years (mean and median age 61 years) were enrolled in the
study. Lymphoid malignancy was diagnosed in 22 patients
and myeloid malignancy in 9 patients. T-cell lymphoid
malignancies included anaplastic large cell lymphoma in
2 patients, angioimmunoblastic T-cell lymphoma in
2 patients, enteropathy-associated T-cell lymphoma in
1 patient, and peripheral T-cell lymphoma not otherwise
specified in 4 patients. B-cell lymphoid malignancies
included follicular lymphoma in 2 patients, chronic lympho-
cytic leukemia (CLL) in 3 patients, diffuse large B-cell
lymphoma in 3 patients, T-cell/histiocyte-rich B-cell lym-
phoma in 1 patient, and gray-zone diffuse large B-cell
lymphoma/Burkitt lymphoma in 1 patient. Hodgkin lym-
phoma (HL) included lymphocyte depleted in 1 patient, not
specified HL in 1 patient, composite EBV-driven HL/non-HL
in 1 patient. Patient characteristics are shown in Table II.
Diagnosis of HLH criteria
Fever (median 39 8C; range 38.2–40.6 8C) was present in 28
(90%) patients. The remaining three patients had median
body temperature of 37.4 8C (range 36.9–37.8 8C).
Splenomegaly occurred in 17/28 (61%) patients; one
patient had earlier undergone splenectomy and in two
patients a spleen size was not determined.
Examination of fine needle BM aspirates disclosed hemo-
phagocytosis in 22/30 (73%) patients. BM examination was
not performed in 1 patient.
Whole blood hemoglobin concentration (Hb) ranged from
69 to 129 g/L (ref.: 134–170 g/L). Thus, anemia was found inTable II – Patient characteristics




Age at the time of HLH diagnosis (years)
Mean  SD 60.7  14.3





NK/T-cell lymphoma 9 (29%)
B-cell lymphoma 10 (32%)





Polycythemia vera 1 (3%)
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome;
SD, standard deviation.all patients and mean Hb was 88.6  12.5 g/L. HLH-2004
criterion of Hb <90 g/L was fulfilled in 17/31 (55%) patients.
Neutropenia with neutrophils <1.0  109/L was present in
12/31 (39%) patients.
Thrombocytopenia (platelets /PLT/ ref.: 145–348  109/L)
was revealed in 30/31 (97%) patients. Mean PLT count was
44.1  46.7  109/L, median PLT was 28  109/L, and PLT
range was 5–344  109/L. HLH-2004 criterion of PLT
<100  109/L was fulfilled in vast majority (29/31, 93%) of
studied patients.
Serum triglyceride level 3.0 mmol/L (ref.: 0.45–2.6) was
found in 35% (11/31) of patients. Serum fibrinogen concen-
tration (ref.: 2.0–4.2 g/L) was decreased 1.5 g/L in 29% (9/31)
patients. However, HLH-2004 criterion of hypertriglyceride-
mia 3.0 mmol/L and/or hypofibrinogenemia 1.5 g/L was
fulfilled in 48% (15/31) patients.
Serum ferritin concentration (ref.: 30–350 mg/L) at the
time of hM-HLH diagnosis was elevated in all but one
patient. Mean ferritinemia was 48 635  119 886 mg/L (med-
ian 14 727 mg/L, range 96–645 291 mg/L). HLH-2004 criterion,
hyperferritinemia 500 mg/L was met in 97% (30/31) of
patients at the time of HLH diagnosis.
The level of sIL-2Ra in serum was measured in 30/31
patients and in 97% (29/30) of cases it was elevated 2400 U/
mL.
Twenty-one patients fulfilled at least five HLH-2004 cri-
teria and 10 patients fulfilled at least four HLH-2004 criteria
(all of them presenting at least two of the following features:
sIL-2Ra 2400 U/mL, hemophagocytosis in BM, and hyperfer-
ritinemia 10 000 mg/L) (Fig. 1). The incidences of tested HLH-
2004 criteria for the study group are shown in Fig. 2.
Serum B2M in newly diagnosed hM-HLH
The serum concentration of B2M was elevated in all of the
examined hM-HLH patients at the time of diagnosis of hM-
HLH. Mean and median serum B2M concentrations were 5.3
and 4.2 mg/L, respectively (range 2–17 mg/L). We have not
found any significant differences in terms of the studied
serum B2M concentrations between patients with T/NK-cell
lymphomas, B-cell lymphomas, and myeloid malignancies
(Fig. 3).Fig. 1 – The number of examined and fulfilled HLH-2004
criteria at the time of HLH diagnosis in 31 patients with
hematological malignancies
Fig. 3 – Serum B2M concentration in hM-HLH depending on
background malignancy
Fig. 4 – Overall survival of patients with h
Fig. 2 – The incidence of clinical and laboratory HLH-2004
criteria in 31 patients with newly diagnosed HLH and
hematological malignancy
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In 10 patients HLH therapy started before confirmation of
HLH diagnosis, based on clinical suspicion of HLH. Eight
patients started HLH therapy on the day of HLH diagnosis.
In 13 patients, HLH therapy started in median 4 days after
the HLH diagnosis.
The median OS for the entire studied group was 46 days
(Fig. 4). Probably due to the small subgroups, we have not
found any significant difference in terms of survival among
patients depending on their background malignancy. How-
ever, the median OS for patients with hM-HLH and B-cell
lymphoma was 228 days compared with 44 days for T/NK-
cell lymphoma and 40 days for myeloid malignancy
(Fig. 5).
Discussion
M-HLH can occur as the first manifestation of an occult
malignancy, before the start or during treatment of a known
malignancy, or as the sign of a malignancy relapse or
transformation to a more aggressive disease form [7, 14].
There is a rising body of evidence that M-HLH can occur in
the course of all hematological malignancies, and not
mainly in T/NK-cell lymphomas as it was thought pre-
viously [2, 10–14, 17, 20]. The association between serum
B2M levels and HLH has previously rarely been reported,
and we were able to find only a few such studies in the
literature [5, 16, 21–23].
Increased concentrations of B2M were observed in
patients with hematopoietic malignancies, such as multiple
myeloma, CLL, and HL. Moreover, serum concentration of
B2M has been shown to be an independent prognostic factor
for these diseases [24–26], as well as a predictor of total
mortality in a general population of older adults [27].
Elevated levels of serum B2M reflect T-cell activation [5].
In this study, we have found that serum concentrations of
B2M were elevated in 100% of adult patients with hM-HLH,ematological malignancies and HLH
Fig. 5 – Overall survival of patients with hM-HLH depending
on malignancy type
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shown).
Similarly, in the study by Jiang et al. the serum levels of
B2M were markedly high in almost all patients with HLH,
especially those with lymphoma-associated HLH (LAHS) [21].
The authors have also found that OS was significantly
shorter in LAHS patients with serum B2M levels 4.03 mg/L
compared to <4.03 mg/L ( p < 0.001). However, we could not
confirm the aforementioned results using the above cutoff
for serum B2M in our cohort (Fig. 6). Based on their study,
Jiang et al. proposed that serum B2M concentration was
a powerful and independent prognostic factor for OS in
patients with LAHS [21].
Wakabayashi et al. analyzed serum B2M levels in 23
females (aged 39  16.4 years, range 16–75 years) with
autoimmune-associated HLH. Sixteen patients had systemic
lupus erythematosus (SLE) and 7 patients had adult-onset
Still's disease (AOSD) [16]. Serum B2M concentration wasFig. 6 – Overall survival of patients with hM-HLH in
subgroups with serum B2M concentration I4.03 mg/L
(curve A) and <4.03 mg/L (curve B)compared between the active and inactive statuses of SLE
and AOSD. The serum B2M level was high in the active
status of underlying diseases and decreased significantly
after the therapy (3.5  1.4 vs. 2.1  0.8 mg/L, p < 0.001).
Among patients with active disease status, the B2M level
was higher in 5 patients with HLH than in patients without
HLH (4.9  1.8 vs. 3.3  1.4 mg/L, p < 0.05). These authors
conclude that serum B2M concentration would be a useful
indicator of disease activity and development of HLH in
patients with SLE and AOSD [16].
In another study Kaito et al. analyzed 34 patients with
HLH (5 patients had hematological malignancy; 6 patients
had infections; 1 patient had SLE, AOSD, and chronic renal
failure each; and 20 patients had no obvious underlying
disease) [28]. They concluded that the risk factors associated
with death were age >30 years, DIC, increased ferritin and
B2M concentrations, and anemia accompanied by thrombo-
cytopenia and jaundice.
In the abstract, Machowicz et al. showed that 12 of 13
patients with unspecified forms of HLH (median age 30
years, range 17–80 years) had elevated serum B2M concen-
trations (median 5.1 mg/L, range 1.83–15.3 mg/L) [23]. The
authors speculate whether B2M could be useful as a marker
of HLH activity.
The mechanism inducing secondary HLH, including M-
HLH, is not fully understood. It is believed that immunologi-
cal dysregulation associated with an underlying disease
might be crucial [16]. It has been suggested that the levels of
sIL-2Ra, which is reflective of T-cell activation, and soluble
CD163, which is related to activation of phagocytic macro-
phages, might be useful as diagnostic markers of HLH and
helpful in monitoring disease activity and response to
treatment. Measurements of the levels of these factors or of
cytokines such as IFN-g, TNF-a, and IL-18 may not be easily
available in a timely fashion to aid in the early diagnosis of
HLH [1, 3, 4, 7]. In contrast, serum B2M concentration can be
measured in common clinical laboratories of hospitals and
the result can be obtained in a timely fashion [16]. Serum
B2M level would be a useful indicator of HLH for its early
detection and evaluation afterward, as well as for immedi-
ate therapeutic intervention.
M-HLH is a highly lethal disorder in the adult population
and has the worst outcome in comparison with any other
form of HLH [10, 28–32]. The present study showed that OS
of adults with hM-HLH is particularly dismal. It is possible
that high serum B2M concentrations indicated a high HLH
and/or malignancy activity, which was responsible for
a poor outcome in the present study. Although in many
patients poor outcome depends on malignancy progression,
in some patients the lack of effective M-HLH therapy may
further impede adequate treatment of malignancy. Further
prospective investigations focusing on the question whether
serum B2M can be used as a marker and prognostic factor
in M-HLH or generally in HLH would be of interest.
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